The landscape of antibody therapeutic development is undergoing a profound transformation, driven by the accelerating integration of artificial intelligence (AI)…
Read More
Cellares and Papillon Therapeutics Partner to Automate Manufacturing of Investigational Therapy for Friedreich’s Ataxia
In a significant development for the rare disease community, Cellares and Papillon Therapeutics have announced a strategic collaboration aimed at…
Read More
Samsung Biologics to Acquire PolyPeptide Group for SFr1.46 Billion, Expanding Peptide Therapeutics and CDMO Capabilities
Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in…
Read More
Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics
In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Talawar Therapeutics and JATT II Acquisition Complete Business Combination to Advance Novel Immunology Therapeutics
In a significant development poised to reshape the landscape of immunology therapeutics, New Jersey-based Talawar Therapeutics has officially merged with…
Read More
Novartis and Antares Therapeutics Forge Landmark Oncology Collaboration to Tackle Undruggable Cancer Targets
In a significant move poised to accelerate the development of novel cancer therapies, Novartis has entered into a strategic collaboration…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies
Voro Therapeutics and Alloy Therapeutics have announced a significant strategic research partnership aimed at developing a new generation of masked…
Read More
Vedana Therapeutics Secures $46 Million Series A to Advance Next-Generation Migraine Prevention Therapies Targeting PACAP
Seattle-based biotech firm Vedana Therapeutics has successfully closed a $46 million Series A financing round, a significant infusion of capital…
Read More
